The FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial

NCT07761728 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-08-12

No results posted yet for this study

Summary
Conditions
Interventions
Sponsors
Investigators
Design
Eligibility
Timeline
Countries
Locations
Related
Entities

Summary

This study seeks to evaluate if the diagnostic performance of 18F-flurpiridaz positron emission tomography (PET) myocardial perfusion imaging (MPI), given the radiotracer's properties, is non-inferior to the currently most widely utilized PET MPI radiopharmaceutical, 82Rb-chloride.

Conditions

Coronary Artery Disease
Coronary Microvascular Disease

Sponsors & Collaborators

VA Greater Los Angeles Healthcare System
collaborator FED
University of California, Los Angeles
lead OTHER

Eligibility

Min Age: 18 Years
Sex: ALL
Healthy Volunteers: No

Timeline & Regulatory

Start: 2025-08-13
Primary Completion: 2026-12-31
Completion: 2027-01-31

Countries

United States

Study Locations

More Related Trials

Entities

Diseases

Coronary Artery Disease

Companies

University of California, Los Angeles

Summary

Conditions

Sponsors & Collaborators

Eligibility

Timeline & Regulatory

Countries

Study Locations

Related Clinical Trials

Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Fatty Acid Radiotracer Comparison Study in Heart Failure Patients

Pivotal, Single-arm Clinical Trial to Assess the Efficacy and Safety of the MedHub AutocathFFR Software Device

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

More Related Trials

Entities